ArticleNature communications2023
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies.European journal of haematology · 2026Review
- From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma.Frontiers in immunology · 2026Review
- Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.bioRxiv : the preprint server for biology · 2025Article
- Impact of the kinetics of circulating anti-BCMA CAR-T cells and normal lymphocytes on the outcome of MM patients.HemaSphere · 2025Article
- Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia.Nature communications · 2025Article
- Human preclinical multiple myeloma in vitro models for disease modeling and therapy screening.Journal of biological engineering · 2025Review
- Characteristics of long term survivors of multiple myeloma after autologous stem cell transplantation: a retrospective analysis from a tertiary care centre in India.The Lancet regional health. Southeast Asia · 2025Article
- Molecular and immunological determinants of long-term survival in multiple myeloma.Blood advances · 2025Review
- Knowledge-informed multimodal cfDNA analysis improves sensitivity and generalization in cancer detection.bioRxiv : the preprint server for biology · 2025Article
- Article
- Review
- Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses.medRxiv : the preprint server for health sciences · 2025Article
- T cell phenotype and clonality changes in myeloma patients with short overall survival.JCI insight · 2025Article
- Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma.Nature reviews. Clinical oncology · 2025Review
- Immune responses after one versus two Influenza A/B vaccinations in patients with multiple myeloma.Annals of hematology · 2025Article
- A proinflammatory response and polarized differentiation of stromal elements characterizes the murine myeloma bone marrow niche.Experimental hematology & oncology · 2025Article
- Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion?Annals of hematology · 2025Review
- Machine learning reveals distinct T-cell receptor clusters in plasma cell dyscrasias compared to healthy controls.PloS one · 2025Article
- Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma.Leukemia · 2024Article
- CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma.Leukemia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 10 institutions in 3 countries.
Funding
Abstract
The role of the immune microenvironment in maintaining disease remission in patients with multiple myeloma (MM) is not well understood. In this study, we comprehensively profile the immune system in patients with newly diagnosed MM receiving continuous lenalidomide maintenance therapy with the aim of discovering correlates of long-term treatment response. Leveraging single-cell RNA sequencing and T cell receptor β sequencing of the peripheral blood and CyTOF mass cytometry of the bone marrow, we longitudinally characterize the immune landscape in 23 patients before and one year after lenalidomide exposure. We compare patients achieving sustained minimal residual disease (MRD) negativity to patients who never achieved or were unable to maintain MRD negativity. We observe that the composition of the immune microenvironment in both the blood and the marrow varied substantially according to both MRD negative status and history of autologous stem cell transplant, supporting the hypothesis that the immune microenvironment influences the depth and duration of treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.